72 related articles for article (PubMed ID: 22087021)
41. Effects of lipid interaction on the lysine microenvironments in apolipoprotein E.
Lund-Katz S; Zaiou M; Wehrli S; Dhanasekaran P; Baldwin F; Weisgraber KH; Phillips MC
J Biol Chem; 2000 Nov; 275(44):34459-64. PubMed ID: 10921925
[TBL] [Abstract][Full Text] [Related]
42. The Apolipoprotein E Mimetic Peptide AEM-2 Attenuates Mitochondrial Injury And Apoptosis In Human THP-1 Macrophages.
Giordano-Mooga S; Datta G; Wolkowicz P; Garber DW; Palgunachari M; White CR; Anantharamaiah GM
Curr Top Pept Protein Res; 2018; 19():15-25. PubMed ID: 29955206
[TBL] [Abstract][Full Text] [Related]
43. Preparation and activity analysis of recombinant human high-density lipoprotein.
Su M; Chang W; Shi K; Wang D; Wang M; Xu T; Yan W
Assay Drug Dev Technol; 2012 Oct; 10(5):485-91. PubMed ID: 22897450
[TBL] [Abstract][Full Text] [Related]
44. Recombinant high-density lipoproteins and their use in cardiovascular diseases.
Cao YN; Xu L; Han YC; Wang YN; Liu G; Qi R
Drug Discov Today; 2017 Jan; 22(1):180-185. PubMed ID: 27591840
[TBL] [Abstract][Full Text] [Related]
45. Restriction isotyping of apolipoprotein E.
Benvenga S
Ann Intern Med; 1995 Jan; 122(1):68-9. PubMed ID: 7985900
[No Abstract] [Full Text] [Related]
46. The potential of apolipoprotein mimetic peptides in the treatment of atherosclerosis.
Leman LJ
Clin Lipidol; 2015 Jun; 10(3):215-217. PubMed ID: 27110290
[No Abstract] [Full Text] [Related]
47. Recombinant humanized collagen remodels endometrial immune microenvironment of chronic endometritis through macrophage immunomodulation.
You S; Zhu Y; Li H; He F; Liu S; Yang X; Wang L; Zeng H; Dai J; Hu L
Regen Biomater; 2023; 10():rbad033. PubMed ID: 37122820
[TBL] [Abstract][Full Text] [Related]
48. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases.
Chew NWS; Chong B; Ng CH; Kong G; Chin YH; Xiao W; Lee M; Dan YY; Muthiah MD; Foo R
Front Genet; 2022; 13():971484. PubMed ID: 36035124
[TBL] [Abstract][Full Text] [Related]
49. Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis.
Benitez Amaro A; Solanelles Curco A; Garcia E; Julve J; Rives J; Benitez S; Llorente Cortes V
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441867
[TBL] [Abstract][Full Text] [Related]
50. Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.
Wolska A; Reimund M; Sviridov DO; Amar MJ; Remaley AT
Cells; 2021 Mar; 10(3):. PubMed ID: 33800446
[TBL] [Abstract][Full Text] [Related]
51. Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features.
Tudorache IF; Trusca VG; Gafencu AV
Comput Struct Biotechnol J; 2017; 15():359-365. PubMed ID: 28660014
[TBL] [Abstract][Full Text] [Related]
52. A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice.
Xu Y; Liu H; Liu M; Li F; Liu L; Du F; Fan D; Yu H
Am J Transl Res; 2016; 8(8):3482-92. PubMed ID: 27648138
[TBL] [Abstract][Full Text] [Related]
53. High-density lipoprotein mimetics: promises and challenges.
Sviridov D; Remaley AT
Biochem J; 2015 Dec; 472(3):249-59. PubMed ID: 26613945
[TBL] [Abstract][Full Text] [Related]
54. Evolving targets for lipid-modifying therapy.
Do RQ; Nicholls SJ; Schwartz GG
EMBO Mol Med; 2014 Oct; 6(10):1215-30. PubMed ID: 25172365
[TBL] [Abstract][Full Text] [Related]
55. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.
Ditiatkovski M; D'Souza W; Kesani R; Chin-Dusting J; de Haan JB; Remaley A; Sviridov D
PLoS One; 2013; 8(7):e68802. PubMed ID: 23874769
[TBL] [Abstract][Full Text] [Related]
56. A new recombinant human apolipoprotein E mimetic peptide with high-density lipoprotein binding and function enhancing activity.
Zhao W; Du F; Zhang M; Sun S; Yu H; Fan D
Exp Biol Med (Maywood); 2011 Dec; 236(12):1468-76. PubMed ID: 22087021
[TBL] [Abstract][Full Text] [Related]
57. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
[TBL] [Abstract][Full Text] [Related]
58. Bacterial overexpression, isotope enrichment, and NMR analysis of the N-terminal domain of human apolipoprotein E.
Fisher CA; Wang J; Francis GA; Sykes BD; Kay CM; Ryan RO
Biochem Cell Biol; 1997; 75(1):45-53. PubMed ID: 9192073
[TBL] [Abstract][Full Text] [Related]
59. Replacement of helix 1' enhances the lipid binding activity of apoE3 N-terminal domain.
Redmond KA; Murphy C; Narayanaswami V; Kiss RS; Hauser P; Guigard E; Kay CM; Ryan RO
FEBS J; 2006 Feb; 273(3):558-67. PubMed ID: 16420479
[TBL] [Abstract][Full Text] [Related]
60. The future of apolipoprotein E mimetic peptides in the prevention of cardiovascular disease.
Valanti EK; Chroni A; Sanoudou D
Curr Opin Lipidol; 2019 Aug; 30(4):326-341. PubMed ID: 31157629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
